Skip to main content
    P

    Protalix Biotherapeutics Inc (PLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $3.02
    -0.03 (-0.98%)

    Market Cap: $257.17M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Protalix Biotherapeutics Inc (PLX) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Protalix Biotherapeutics (PLX) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, Protalix Biotherapeutics reported EPS of $0.05, above the -$0.02 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    46%(18/39)
    Avg Surprise
    -0.94%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 16, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.02
    Range-$0.04 - $0.01
    3 analysts
    Revenue Consensus
    $12.98M
    Range$9.31M - $17.01M
    3 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.01
    Range$0.01 - $0.01
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.010.0%
    60d ago$0.010.0%
    30d ago$0.010.0%
    7d ago$0.010.0%
    Current$0.01
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    PLX has an expected report date of Mar 16, 2027.

    PLX Earnings Call

    The latest PLX earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, PLX beat 18, missed 19 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $21.93M, up 22.9% from $17.85M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.05-$0.02-$0.05 - $0.01+350.00%Beat+66.7%20 up, 0 downNov 10, 2026$21.93M
    Jun 30, 2026$0.05-$0.01-$0.03 - $0.01+600.00%BeatN/A20 up, 1 downAug 12, 2026$19.90M
    Mar 31, 2026$0.22-$0.01-$0.01 - -$0.01N/AN/AN/A10 up, 1 downMay 13, 2026$33.75M
    Dec 31, 2025-$0.07$0.04-$0.03 - $0.04-300.00%Miss-177.8%20 up, 1 downMar 18, 2026$9.12M
    Sep 30, 2025$0.03$0.06$0.04 - $0.07-50.00%Miss0.0%20 up, 1 downNov 13, 2025$17.85M
    Jun 30, 2025-$0.04$0.03$0.02 - $0.04-233.33%MissN/A20 up, 1 downAug 14, 2025$15.66M
    Mar 31, 2025-$0.05$0.08N/A-162.50%MissN/AN/A0 up, 0 downMay 9, 2025$10.11M
    Dec 31, 2024$0.09$0.07N/A+28.57%BeatN/AN/A0 up, 0 downMar 17, 2025$18.22M
    Sep 30, 2024$0.03$0.06N/A-50.00%MissN/A10 up, 0 downNov 14, 2024$17.96M
    Jun 30, 2024-$0.03$0.02$0.02 - $0.02-250.00%Miss-114.3%10 up, 0 downAug 14, 2024$13.47M
    Mar 31, 2024-$0.06-$0.02N/A-200.00%MissN/AN/A0 up, 0 downMay 10, 2024$3.75M
    Dec 31, 2023-$0.07-$0.03-$0.03 - -$0.03-133.33%MissN/A10 up, 0 downMar 14, 2024$10.49M
    Sep 30, 2023-$0.03-$0.07N/A+57.14%BeatN/A10 up, 0 downNov 6, 2023$10.35M
    Jun 30, 2023$0.21-$0.04-$0.04 - -$0.04+625.00%BeatN/A10 up, 0 downAug 7, 2023$35.08M
    Mar 31, 2023-$0.05-$0.05N/A0.00%In lineN/AN/A0 up, 0 downMay 4, 2023$9.59M
    Dec 31, 2022-$0.07-$0.15-$0.15 - -$0.15+53.33%BeatN/A10 up, 0 downFeb 27, 2023$8.62M
    Sep 30, 2022-$0.07-$0.15-$0.15 - -$0.15+53.33%BeatN/A10 up, 0 downNov 14, 2022$14.18M
    Jun 30, 2022-$0.11-$0.18N/A+38.89%BeatN/AN/A0 up, 0 downAug 15, 2022$8.75M
    Mar 31, 2022-$0.05-$0.04N/A-25.00%MissN/AN/A0 up, 0 downMay 16, 2022$16.09M
    Dec 31, 2021-$0.15-$0.11-$0.11 - -$0.11-36.36%Miss-1600.0%1N/AMar 31, 2022$8.55M
    Sep 30, 2021-$0.09-$0.12N/A+25.00%BeatN/AN/AN/ANov 15, 2021$12.05M
    Jun 30, 2021-$0.25-$0.10N/A-150.00%MissN/A1N/AAug 16, 2021$6.43M
    Mar 31, 2021-$0.14-$0.17-$0.17 - -$0.17+17.65%Beat-240.0%1N/AMay 14, 2021$11.32M
    Dec 31, 2020$0.01-$0.08-$0.13 - -$0.04+112.50%Beat0.0%2N/AMar 30, 2021$41.14M
    Sep 30, 2020-$0.14-$0.08-$0.08 - -$0.08-75.00%MissN/A1N/AOct 29, 2020$10.79M
    Jun 30, 2020-$0.13-$0.20-$0.31 - -$0.10+35.00%BeatN/A2N/AAug 10, 2020$10.97M
    Mar 31, 2020$0.10-$0.30-$0.30 - -$0.30+133.33%BeatN/A1N/AJun 1, 2020N/A
    Dec 31, 2019$0.01-$0.63N/A+101.59%BeatN/AN/AN/AMar 12, 2020$17.76M
    Sep 30, 2019-$0.20-$0.35-$0.60 - -$0.10+42.86%BeatN/A2N/ANov 7, 2019$14.25M
    Jun 30, 2019-$0.50-$0.30-$0.40 - -$0.20-66.67%MissN/A2N/AAug 8, 2019$12.25M
    Mar 31, 2019-$0.50-$0.25-$0.40 - -$0.10-100.00%MissN/A2N/AMay 6, 2019$10.44M
    Dec 31, 2018-$0.37-$0.45-$0.60 - -$0.30+17.78%BeatN/A2N/AMar 18, 2019N/A
    Sep 30, 2018-$1.00-$0.40-$0.60 - -$0.20-150.00%MissN/A2N/ANov 7, 2018$12.34M
    Jun 30, 2018-$0.80-$0.40-$0.70 - -$0.40-100.00%MissN/A2N/AAug 9, 2018$4.84M
    Mar 31, 2018-$0.60-$0.90-$1.00 - -$0.80+33.33%BeatN/A2N/AMay 9, 2018$6.71M
    Dec 31, 2017-$0.60-$0.60-$0.80 - -$0.400.00%In lineN/A2N/AMar 6, 2018$4.30M
    Sep 30, 2017-$0.90-$0.45N/A-100.00%MissN/A1N/ANov 8, 2017$7.53M
    Jun 30, 2017-$1.08-$0.35-$0.60 - -$0.10-208.57%MissN/A2N/AAug 9, 2017$6.36M
    Mar 31, 2017-$0.50-$0.90-$1.00 - -$0.70+44.44%BeatN/A2N/AMay 10, 2017$2.89M
    Dec 31, 2016-$1.27-$1.10N/A-15.45%Miss-116.5%N/AN/AMar 16, 2017$2.08M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.13, after $0.03 the year before. It was -$3.97 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.13-533.3%
    Dec 31, 2024$0.03N/A
    Dec 31, 2023$0.06N/A
    Dec 31, 2022-$0.30N/A
    Dec 31, 2021-$0.63N/A
    Dec 31, 2020-$0.16N/A
    Dec 31, 2019-$1.19N/A
    Dec 31, 2018-$2.77N/A
    Dec 31, 2017-$3.08N/A
    Dec 31, 2016-$3.97N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 1,900 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20261,8506
    2025Q4Dec 31, 20252,7186
    2025Q3Sep 30, 20253,4597
    2025Q2Jun 30, 20252,9747
    2025Q1Mar 31, 20253,5627
    2024Q3Sep 30, 20243,1478
    2024Q2Jun 30, 20243,2756

    2026Q1 Earnings Call

    Opening remarks

    Mike Moyer Investor Relations Thank you, operator, and welcome to the Protalix BioTherapeutics Q1 2026 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO of Protalix; and Gilad Mamlok, Senior Vice President and Chief Financial Officer. A press release announcing the financial results and corporate updates was issued this morning and is available now on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Protalix's filings with the U.S. Securities and Exchange Commission. I will now turn the call over to Mr. Bashan. Dror?

    Dror Bashan President and CEO Thank you, Mike, and thank you, everyone, for joining our Q1 2026 financial results and business update call. I want to begin by highlighting two points that underscore the strength of our business today. First, during the quarter, we received a $25 million milestone from Chiesi, following the European Commission approval of Elfabrio's every 4-week dosing regimen. As a result, we ended the first quarter of this year with $51 million in cash, providing us with a strong balance sheet and substantial financial flexibility and sufficient funds to support our ongoing operations as well as our Phase II RELEASE study with PRX-115. Second, we are reaffirming our 2026 guidance. We continue to expect total revenue for the year to range from approximately $78 million to $83 million, inclusive of the $25 million milestone received from Chiesi. Within that outlook, we anticipate Elfabrio revenues, excluding milestones, of approximately $33 million to $35 million and Elelyso revenues of approximately $20 million to $23 million. Taken together, this guidance reflects the strength of our commercial partnerships and our confidence in execution across our business for the year ahead. We entered 2026 with good momentum with the regulatory progress for Elfabrio in Europe, which triggered a $25 million milestone payment, the continued enrollment of our PRX-115 Phase II RELEASE study and a growing focus on our rare renal disease preclinical pipeline. We remain confident in our strategy for the years ahead. Our partner, Chiesi, continues to execute well with Elfabrio across approved markets. Following the European Commission's recent approval of the every 4-week regimen, we believe Elfabrio is well positioned to meaningfully reduce treatment burden for eligible patients in the European Union without compromising efficacy. This added dosing flexibility strengthens Elfabrio's competitive position and supports broader adoption over time. In the United States, the FDA-approved dosing regimen remains unchanged.

    Frequently Asked Questions About PLX

    When is Protalix Biotherapeutics's next earnings date?

    Protalix Biotherapeutics's next earnings report is expected for Mar 16, 2027.

    Did PLX beat earnings estimates last quarter?

    Yes. Protalix Biotherapeutics reported EPS of $0.05 for the quarter ended Sep 30, 2026, above the -$0.02 estimate, a 350.00% surprise.

    What EPS do analysts expect from PLX next quarter?

    The consensus EPS estimate for Protalix Biotherapeutics for the quarter ending Dec 31, 2026 is -$0.02 from 3 analysts, with estimates from -$0.04 to $0.01.

    How often does PLX beat earnings estimates?

    Protalix Biotherapeutics beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of +22.84%.